Psoriasis

The increasing prevalence of this chronic condition in children necessitates understanding its broader impacts and management strategies.

Ben Lockshin, MD, FAAD, shared his insights on the latest advancements in oral options for psoriasis therapies.

All domains of the DLQI and CDLQI experienced improvements through 108 weeks, according to a poster presented at the SPD's annual meeting.

This professional summary discusses the definitions of loss of response and loss of efficacy in patient therapy, while also comparing response rates across different psoriasis treatments.

Key opinion leaders examine patient response rates to biologic treatments and provide critical insights on transitioning between therapies to optimize patient outcomes.

Christopher Bunick, MD, PhD, provides insights into new research exploring bimekizumab’s unique binding to IL-17F and IL-17A by analyzing crystals of bimekizumab fragment antigen-binding.

Phase 3 trials found the treatment demonstrated efficacy as early as week 1 of treatment and sustained this response through week 52.

The experts discuss combination therapy approaches, safety considerations, and targeted interleukin-17 systemic treatments for plaque psoriasis.

Key opinion leaders explore the management of plaque psoriasis, addressing treatment-related challenges and emphasizing the importance of effective communication for informed decision-making in therapy selection.

Iain Stuart, PhD, discusses VYN202's status and potential in psoriasis and immuno-inflammatory diseases.

Pyzchiva will be commercialized by Sandoz in the United States.

Risankizumab outperformed other biologics in real-world psoriasis treatment, achieving higher PASI 90/100 rates and patient satisfaction.

The key opinion leaders examine a case study of a 42-year-old male patient, detailing the process of treatment selection and shared decision-making that led to improved outcomes.

Medical experts specializing in plaque psoriasis offer a comprehensive overview of the current treatment landscape, its evolution, and the disease's psychological and physical impacts.

Researchers found the assessment accounted for those with moderate impact, allowing clinicians to create improved treatment plans for patients.

Stefan Weiss, MD, MBA, explains next steps for the oral treatment after the completion of phase 1b enrollment.

Sara Osborne, a fourth-year medical student and the lead author on the study, spoke with Dermatology Times on key findings and explain the need for further investigation.

A recent review found that disparities and barriers, such as income, age, and location, can impede patient access to necessary care.

Omar Noor, MD, and a patient with psoriasis share their unique perspectives on moderate to severe plaque psoriasis treatment with tildrakizumab.

Weekend treatment with cyclosporine may be beneficial for patients with moderate to severe psoriasis, according to a new study.

Gottlieb reviews her lecture from the Society for Investigative Dermatology Annual Meeting.

The results indicated improvement in PASI and sPGA scores as well as improvement in quality of life indicators in adults with moderate to severe psoriasis.

Jason Hawkes, MD, MS, gives an overview of what clinicians need to know today about this rare condition.

Ben Lockshin, MD, FAAD, delves into the new generation of oral psoriasis therapies to enhance patient quality of life.

The treatment is the first IL-17 targeting topical therapy being developed for less severe cases of psoriasis.

This research indicates that psychological well-being serves a key role in the management of psoriatic disease.

The study not only showed success for patients with severe psoriasis, but also suggested it may be worth trying before other biologics.

Based on these findings, Innovent plans to submit a New Drug Application to the Center for Drug Evaluation of National Medical Product Administration.

Researchers from NYU Langone recently published a study clarifying the role of HIF-1-alpha in inflammation and psoriasis, which has been unclear until now.

A study out of Japan found some biologics used to treat psoriasis may require higher dose escalation than others.